Inclusion criteria include:~1. Patient with dementia of Alzheimer's type, according to the Diagnostic and
Statistical Manual of Mental Disorders criteria (DSM-IV)~2. Patient with probable Alzheimer' disease according
to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease
and Related Disorders Association criteria (NINCDS-ADRDA)~3. Patient with MMSE ≥ 12 and ≤ 25 at baseline~4.
Patient treated for a minimum of 6 months with a stable dose of cholinesterase inhibitors (donepezil,
rivastigmine or galantamine) at baseline, and/or a stable dose of memantine for a minimum of 6 months at
baseline, with no changes foreseen in therapy throughout the study.~
